On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading
(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading
On March 1, 2021, Knowledge Ecology International (KEI) sent a letter to Dr. Ngozi Okonjo-Iweala, the new Director-General of the World Trade Organization (WTO) regarding the WTO’s COVID-19 response. In the letter, KEI urged Dr. Ngozi to fully step into… Continue Reading
New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading
On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading
On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading
(More on the USTR Special 301. link) On Thursday January 28, 2021, Knowledge Ecology International (KEI) submitted comments to the US Trade Representative’s (USTR) Special 301 Review process. The USTR conducts an annual review of other countries’ intellectual property policies… Continue Reading
Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like… Continue Reading
(Update: The NIH provided a response to our comments on January 19, 2021) On January 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Use… Continue Reading
(Updated for KEI’s corrected brief). On Wednesday December 16, 2020, Knowledge Ecology International (KEI) filed an amicus curiae brief in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. (“GSK”, “Teva”). The case concerns secondary indications of medicines, and whether Teva induced… Continue Reading